{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:40:20Z","timestamp":1791186020795,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In this 3-yr, randomized, double-blind, placebo- and active-controlled study, healthy postmenopausal women with osteoporosis (55\u201385 yr of age) were treated with bazedoxifene 20 or 40 mg\/d, raloxifene 60 mg\/d, or placebo. The primary endpoint was incidence of new vertebral fractures after 36 mo; secondary endpoints included nonvertebral fractures, BMD, and bone turnover markers. Among 6847 subjects in the intent-to-treat population, the incidence of new vertebral fractures was significantly lower (p &amp;lt; 0.05) with bazedoxifene 20 mg (2.3%), bazedoxifene 40 mg (2.5%), and raloxifene 60 mg (2.3%) compared with placebo (4.1%), with relative risk reductions of 42%, 37%, and 42%, respectively. The treatment effect was similar among subjects with or without prevalent vertebral fracture (p = 0.89 for treatment by baseline fracture status interaction). The incidence of nonvertebral fractures with bazedoxifene or raloxifene was not significantly different from placebo. In a posthoc analysis of a subgroup of women at higher fracture risk (femoral neck T-score \u2264 \u20133.0 and\/or \u22651 moderate or severe vertebral fracture or multiple mild vertebral fractures; n = 1772), bazedoxifene 20 mg showed a 50% and 44% reduction in nonvertebral fracture risk relative to placebo (p = 0.02) and raloxifene 60 mg (p = 0.05), respectively. Bazedoxifene significantly improved BMD and reduced bone marker levels (p &amp;lt; 0.001 versus placebo). The incidence of vasodilatation, leg cramps, and venous thromboembolic events was higher with bazedoxifene and raloxifene compared with placebo. In conclusion, bazedoxifene significantly reduced the risk of new vertebral fracture in postmenopausal women with osteoporosis and decreased the risk of nonvertebral fracture in subjects at higher fracture risk.<\/jats:p>","DOI":"10.1359\/jbmr.080710","type":"journal-article","created":{"date-parts":[[2008,7,29]],"date-time":"2008-07-29T15:26:50Z","timestamp":1217345210000},"page":"1923-1934","source":"Crossref","is-referenced-by-count":419,"title":["Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial"],"prefix":"10.1093","volume":"23","author":[{"given":"Stuart L","family":"Silverman","sequence":"first","affiliation":[{"name":"Cedars-Sinai Medical Center and University of California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Center for Clinical and Basic Research, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry K","family":"Genant","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, and Synarc, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodan","family":"Vukicevic","sequence":"additional","affiliation":[{"name":"University of Zagreb School of Medicine, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R","family":"Zanchetta","sequence":"additional","affiliation":[{"name":"University of El Salvador, Metabolic Research Institute, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobie J","family":"de Villiers","sequence":"additional","affiliation":[{"name":"Panorama MediClinic and University of Stellenbosch, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger D","family":"Constantine","sequence":"additional","affiliation":[{"name":"Wyeth Research, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadi A","family":"Chines","sequence":"additional","affiliation":[{"name":"Wyeth Research, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020319470306800_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10067-006-0265-7","article-title":"The global perspective of osteoporosis: The ILAR lecture, June 2004, Berlin","volume":"25","author":"Woolf","year":"2006","journal-title":"Clin Rheumatol"},{"key":"2024020319470306800_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/PL00004148","article-title":"World-wide projections for hip fracture","volume":"7","author":"Gullberg","year":"1997","journal-title":"Osteoporos Int"},{"key":"2024020319470306800_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000063449","article-title":"Epidemiology of osteoporotic fractures","volume":"54","author":"Dennison","year":"2000","journal-title":"Horm Res"},{"key":"2024020319470306800_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jbmr.5650070902","article-title":"Perspective. How many women have osteoporosis?","volume":"7","author":"Melton","year":"1992","journal-title":"J Bone Miner Res"},{"key":"2024020319470306800_bib5","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1532-5415.1995.tb05557.x","article-title":"Late physical and functional effects of osteoporotic fracture in women: The Rancho Bernardo Study","volume":"43","author":"Greendale","year":"1995","journal-title":"J Am Geriatr Soc"},{"key":"2024020319470306800_bib6","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1996.00440130053006","article-title":"Mortality following fractures in older women. The study of osteoporotic fractures","volume":"156","author":"Browner","year":"1996","journal-title":"Arch Intern Med"},{"key":"2024020319470306800_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s001980070075","article-title":"Risk of mortality following clinical fractures","volume":"11","author":"Cauley","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020319470306800_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2024020319470306800_bib9","first-page":"115","article-title":"Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"2024020319470306800_bib10","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1172\/JCI28550","article-title":"Estrogen deficiency and bone loss: An inflammatory tale","volume":"116","author":"Weitzmann","year":"2006","journal-title":"J Clin Invest"},{"key":"2024020319470306800_bib11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","article-title":"Sex steroids and the construction and conservation of the adult skeleton","volume":"23","author":"Riggs","year":"2002","journal-title":"Endocr Rev"},{"key":"2024020319470306800_bib12","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00198-006-0187-x","article-title":"Osteoporosis prevention and therapy: Preserving and building strength through bone quality","volume":"17","author":"Kleerekoper","year":"2006","journal-title":"Osteoporos Int"},{"key":"2024020319470306800_bib13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bone.2007.06.010","article-title":"Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?","volume":"41","author":"Seeman","year":"2007","journal-title":"Bone"},{"key":"2024020319470306800_bib14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/01.gme.0000222475.93345.b3","article-title":"Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society","volume":"13","author":"North American Menopause Society","year":"2006","journal-title":"Menopause"},{"key":"2024020319470306800_bib15","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/01.AOG.0000163253.27610.b9","article-title":"Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women","volume":"105","author":"Ronkin","year":"2005","journal-title":"Obstet Gynecol"},{"key":"2024020319470306800_bib16","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1210\/en.2005-0030","article-title":"Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity","volume":"146","author":"Komm","year":"2005","journal-title":"Endocrinology"},{"key":"2024020319470306800_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1749-6632.2001.tb04039.x","article-title":"Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation","volume":"949","author":"Komm","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"2024020319470306800_bib18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo- and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020319470306800_bib19","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.5650110716","article-title":"Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis","volume":"11","author":"Genant","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020319470306800_bib20","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020319470306800_bib21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","article-title":"Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures","volume":"14","author":"Black","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024020319470306800_bib22","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"2024020319470306800_bib23","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"2024020319470306800_bib24","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2024020319470306800_bib25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"2024020319470306800_bib26","author":"Kanis","year":"2008"},{"key":"2024020319470306800_bib27","author":"World Health Organization Collaborating Centre for Metabolic Bone Diseases"},{"key":"2024020319470306800_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"2024020319470306800_bib29","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"2024020319470306800_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/JCD:7:3:255","article-title":"Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk","volume":"7","author":"Watts","year":"2004","journal-title":"J Clin Densitom"},{"key":"2024020319470306800_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11914-005-0018-6","article-title":"Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction","volume":"3","author":"Miller","year":"2005","journal-title":"Curr Osteoporos Rep"},{"key":"2024020319470306800_bib32","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020319470306800_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","article-title":"Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy","volume":"17","author":"Sarkar","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024020319470306800_bib34","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0002-9343(01)01124-X","article-title":"Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs","volume":"112","author":"Cummings","year":"2002","journal-title":"Am J Med"},{"key":"2024020319470306800_bib35","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1359\/jbmr.1997.12.7.1083","article-title":"Relationship of bone turnover to bone density and fractures","volume":"12","author":"Melton","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024020319470306800_bib36","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"2024020319470306800_bib37","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.AOG.0000137349.79204.b8","article-title":"Safety and adverse effects associated with raloxifene: Multiple outcomes of raloxifene evaluation","volume":"104","author":"Grady","year":"2004","journal-title":"Obstet Gynecol"},{"key":"2024020319470306800_bib38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"2024020319470306800_bib39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2125.2004.02103.x","article-title":"The revision of the Declaration of Helsinki: Past, present and future","volume":"57","author":"Carlson","year":"2004","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.080710","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/23\/12\/1923\/7599523","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/23\/12\/1923\/7599523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:51:16Z","timestamp":1710341476000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/23\/12\/1923-1934\/7599523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,1]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2008,12,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.080710","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,12,1]]},"published":{"date-parts":[[2008,12,1]]}}}